Fig. 7: Synergy of URB597 with ferroptosis inducers significantly inhibits RCC tumor growth and metastasis in vivo.

786-O cells were treated with the vehicle, URB597 (30 mg/kg), and RSL3 (30 mg/kg) singly or in combination. Tumor size was monitored every other day (A). Photograph of tumors (B), tumor weight (C), and body weight (D) are shown (n = 6 per group). **p < 0.01 (t test). E Survival rates of nude mice treated as in (A) (n = 6 per group). **p < 0.01 (Kaplan–Meier). F Representative images of H&E, Ki67, and 4-HNE IHC staining in tumors harvested from each group. Scale bars: 50 μm. G the results of MDA abundance. H qPCR analysis of the indicated gene expression associated with the PI3K-AKT pathway in tumors harvested from each group. Data are means ± SDs of measurements repeated three times with similar results. **p < 0.01 versus the corresponding control (t test). I, J Representative bioluminescent images of animals treated as in (A) taken on days 0, 7, 14, 21, and 28 after bioluminescent 786-O xenografts (I). Quantification of tumor cells in mice was performed with bioluminescence analysis (L) (n = 6 per group). **p < 0.01 (t test). K Survival rates of nude mice treated as in (A) (n = 6 per group). **p < 0.01 (Kaplan–Meier). L Representative images of hematoxylin and eosin staining of paraffin sections from lungs. Scale bar: 100 μm. Data are means ± SDs of six tumors at each time point.